Ossium Health

+12%

est. 2Y upside i

HealthcareSeries C

Rank

#2525

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Equity upside is modest (expected ~11.5%) due to severe preference overhang ($125M vs $46M valuation) and high dilution risk.

Last updated: July 3, 2026

Bull (10%)+200%

FDA-approved off-the-shelf therapy drives rapid adoption; IPO within 2 years at 8x revenue, but bull cap limits to +200%.

Base (45%)+81%

Steady revenue growth to $28M by 2028; exit multiple converges to 5x, yielding 2x return before 20% dilution.

Bear (45%)-100%

Stagnant revenue or clinical setback; exit below $125M triggers 1x liquidation preference, wiping out common stock.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

26900%

Total funding of $125M exceeds current valuation by 2.7x, meaning common equity is deeply underwater in a downside exit.

Dilution Risk

high

With $125M raised and capital-intensive operations, additional funding is likely within 2 years, diluting existing holders by ~20%.

Secondary Liquidity

active

Recent secondary trades at $46M imply a liquid market for shares, unusual for a private biotech.

Other — 13 roles

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Ossium Health's data — designed to show you've done your homework.

1
“How does Ossium's partnership model with organ procurement organizations sustain a competitive advantage vs NMDP?”
2
“What is your timeline to profitability and how will you fund the next stage of clinical trials?”
3
“How does the current $46M secondary valuation reflect the company's progress since the Series C in 2023?”

Our model estimates +12% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.